Oric Pharmaceuticals, Inc. has announced an update on its enozertinib program, showcasing significant findings from its ongoing Phase 1b trial. The update was presented at the ESMO Congress 2026, highlighting the company's commitment to advancing its clinical development in the oncology sector. This news is particularly important as it outlines the potential for enozertinib to address unmet medical needs in patients with specific mutations of non-small cell lung cancer (NSCLC).
Oric Pharmaceuticals, based in South San Francisco, operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker symbol ORIC. Recent filings indicate that the company is actively engaged in clinical trials and regulatory processes to bring its products to market.
The filing dated October 23, 2026, reveals that Oric presented data from its Phase 1b trial of enozertinib, focusing on patients with locally advanced or metastatic NSCLC with atypical epidermal growth factor receptor (EGFR) mutations. The trial allows for enrollment of patients with untreated brain metastases, a critical factor given the high prevalence of such cases.
According to the filing, key objectives of the trial include assessing safety, determining the recommended Phase 2 dose, and evaluating antitumor activity through various metrics such as objective response rate (ORR) and progression-free survival (PFS). As of the cutoff date of September 4, 2026, data from 26 patients were analyzed, revealing that 65% had brain metastases at baseline, significantly higher than in competitor datasets.
The results indicate that enozertinib was well tolerated, with most treatment-related adverse events being Grade 1 or 2. Notably, there were no severe adverse events leading to treatment discontinuation. The filing highlights that 84% of patients achieved a confirmed systemic ORR as assessed by investigators, while 80% were confirmed by blinded independent central review.
Enozertinib also demonstrated compelling intracranial activity, with 70% of patients showing confirmed intracranial ORR. This is particularly notable given that many patients had untreated CNS metastases, suggesting a potential best-in-class profile for enozertinib in treating brain involvement in NSCLC.
Looking ahead, Oric plans to initiate a global Phase 3 registrational trial, named Redwood-1, in the first half of 2027. This trial will enroll approximately 360 patients and will compare enozertinib to standard treatments like osimertinib or afatinib. The primary endpoints will focus on ORR and PFS, which are critical for potential accelerated approval.
This update not only marks a significant milestone for Oric Pharmaceuticals but also poses implications for the broader pharmaceutical industry, particularly in the oncology sector. Competitors may need to reassess their strategies in light of Oric's promising data and upcoming trial plans.
As the industry continues to evolve, stakeholders will be closely watching Oric's progress with enozertinib and its potential impact on treatment options for patients with NSCLC.